← All trials
NCT03779347
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2019
- Primary completion
- Feb 1, 2020
- Completion date
- May 1, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Centre de Recherche Médicale de LambarénéLead sponsor
- University of TuebingenStudy chair
- Centre de Recherche Médicale de LambarénéReponsible party - principal investigator
- University of TuebingenCollaborator
- Centre de Recherches Médicales de LambarénéOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.